Skip to main content
Top
Published in: Rheumatology International 4/2006

01-02-2006 | Original Article

The importance of alpha-fodrin antibodies in the diagnosis of Sjögren’s syndrome

Authors: Nuran Turkçapar, Umit Olmez, Huseyin Tutkak, Murat Duman

Published in: Rheumatology International | Issue 4/2006

Login to get access

Abstract

Objective: We wanted to determine the prevalence of IgA and IgG antibodies against alpha-fodrin in the patients with primary and secondary Sjögren’s syndrome (SS) and also to compare with anti-Ro and anti-La antibodies in the diagnosis of SS. Methods: We tested the prevalence of anti-alpha-fodrin IgA, IgG, anti-Ro, anti-La antibodies, anti-nuclear antibodies (ANA) and rheumatoid factor (RF) in naive patients with primary (n=20) and secondary SS (n=20) (Rheumatoid Arthritis [RA]+SS, n=10; Systemic Lupus Erythematosus [SLE]+SS, n=10), RA (n=10), SLE (n=10) and in healthy controls (n=20). Salivary gland biopsies were performed in the patients with primary and secondary SS. Results: In primary SS, anti-alpha-fodrin IgA, IgG, anti-Ro and anti-La antibodies were detected as 20, 10, 55 and 20% respectively. In RA+SS, anti-alpha-fodrin IgA was detected to be 10% and IgG was negative; however, anti-Ro antibodies and anti-La antibodies were found to be 40% and 20% respectively. In SLE+SS, anti-alpha-fodrin IgA was found to be 20% and IgG was found to be 10%, but anti-Ro and anti-La antibodies were found to be 90% and 20% respectively. Alpha-fodrin antibodies were not detected in RA, SLE and healthy controls. Conclusion: The detection of anti-alpha-fodrin antibodies by used ELISA does not give much contribution to the diagnosis of SS, and anti-Ro and anti-La are still useful serological markers in the diagnosis of SS.
Literature
1.
go back to reference Pillemer SR, Matteson EL, Jacobson LT et al (2001) Incidence of physician-diagnosed primary Sjögren’s syndrome in residents of Olmsted Country, Minnesota. Mayo Clin Proc 76:593–598 Pillemer SR, Matteson EL, Jacobson LT et al (2001) Incidence of physician-diagnosed primary Sjögren’s syndrome in residents of Olmsted Country, Minnesota. Mayo Clin Proc 76:593–598
2.
go back to reference Pillemer SR (2001) Sjögren’s Syndrome. In: Klippel JH (ed) Primer on the rheumatic disease, 12th edn. Arthritis Foundation, Atlanta, pp 377–384 Pillemer SR (2001) Sjögren’s Syndrome. In: Klippel JH (ed) Primer on the rheumatic disease, 12th edn. Arthritis Foundation, Atlanta, pp 377–384
3.
go back to reference Vitali C, Bombardieri S, Johnson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558PubMed Vitali C, Bombardieri S, Johnson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558PubMed
4.
go back to reference Haneji N, Nakamura T, Takai T et al (1997) Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren’s syndrome. Science 276:604–607 Haneji N, Nakamura T, Takai T et al (1997) Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren’s syndrome. Science 276:604–607
5.
go back to reference Yanagi KN, Ishimaru N, Haneji N, Saegusa K, Saito I, Hayashi Y (1998) Anti-120-kDa α-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren’s syndrome. Eur J Immunol 28:3336–3345 Yanagi KN, Ishimaru N, Haneji N, Saegusa K, Saito I, Hayashi Y (1998) Anti-120-kDa α-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren’s syndrome. Eur J Immunol 28:3336–3345
6.
go back to reference Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K (1999) Anti-α-fodrin antibodies in Sjögren’s syndrome and lupus erythematosus. Arch Dermatol 135:535–539CrossRefPubMed Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K (1999) Anti-α-fodrin antibodies in Sjögren’s syndrome and lupus erythematosus. Arch Dermatol 135:535–539CrossRefPubMed
7.
go back to reference Kobayashi I, Kawamura N, Okano M et al (2001) Anti-α-fodrin autoantibody is an early diagnostic marker for childhood primary Sjögren’s syndrome. J Rheumatol 28:363–365 Kobayashi I, Kawamura N, Okano M et al (2001) Anti-α-fodrin autoantibody is an early diagnostic marker for childhood primary Sjögren’s syndrome. J Rheumatol 28:363–365
8.
go back to reference Maeno N, Takei S, Imanaka H et al (2001) Anti-α-fodrin antibodies in Sjögren’s syndrome in children. J Rheumatol 28:860–864 Maeno N, Takei S, Imanaka H et al (2001) Anti-α-fodrin antibodies in Sjögren’s syndrome in children. J Rheumatol 28:860–864
9.
go back to reference Witte T, Matthias T, Arnett FC et al (2000) IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren’s syndrome. J Rheumatol 27:2617–2620PubMed Witte T, Matthias T, Arnett FC et al (2000) IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren’s syndrome. J Rheumatol 27:2617–2620PubMed
10.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed
11.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 40:1725 Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 40:1725
12.
go back to reference St Clair EW, Burch JA, Saitta M (1994) Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens. Arthritis Rheum 37:1373–1380PubMed St Clair EW, Burch JA, Saitta M (1994) Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens. Arthritis Rheum 37:1373–1380PubMed
13.
go back to reference Ishimaru N, Yanagi K, Ogawa K, Suda T, Saito I, Hayashi Y (2001) Possible role of organ- specific autoantigen for Fas Ligand-mediated activation-induced cell death in murine Sjögren’s syndrome. J Immunol 167:6031–6037PubMed Ishimaru N, Yanagi K, Ogawa K, Suda T, Saito I, Hayashi Y (2001) Possible role of organ- specific autoantigen for Fas Ligand-mediated activation-induced cell death in murine Sjögren’s syndrome. J Immunol 167:6031–6037PubMed
14.
go back to reference Zandbelt MM, Vogelzangs J, van de Putte LB, van Venrooij VJ, van den Hoogen FHJ (2004) Anti-α-fodrin antibodies do not add much to the diagnosis of Sjögren’s syndrome. Arthritis Res Ther 6:R33–R38CrossRefPubMed Zandbelt MM, Vogelzangs J, van de Putte LB, van Venrooij VJ, van den Hoogen FHJ (2004) Anti-α-fodrin antibodies do not add much to the diagnosis of Sjögren’s syndrome. Arthritis Res Ther 6:R33–R38CrossRefPubMed
Metadata
Title
The importance of alpha-fodrin antibodies in the diagnosis of Sjögren’s syndrome
Authors
Nuran Turkçapar
Umit Olmez
Huseyin Tutkak
Murat Duman
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0607-9

Other articles of this Issue 4/2006

Rheumatology International 4/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.